Galectin Therapeutics Says Belapectin Showed 15.9% Placebo-Adjusted Improvement In Predicted Portal Hypertension Risk In MASH Cirrhosis, Per NAVIGATE Trial Analysis
Share
Why It Matters
Galectin's new drug showed better results than a dummy pill. The improvement was small but real, so watch if doctors think it helps patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.